The Academic GI Cancer Consortium (AGICC) is presently represented by Key Opinion Leaders (KOLs) and Top Investigators at the most prestigious institutions in the USA. It represents an innovative research model that brings together a world class team of institutions and investigators to design and rapidly complete clinical trials in gastrointestinal (GI) cancers.
Watch the PharmaVoice One on One video interview below to learn more about the latest in Gastrointestinal Cancer research from Dr. Wells Messersmith, Director of the Academic GI Cancer Consortium and Division Head of Medical Oncology at the University of Colorado Cancer Center.
About Wells Messersmith, MD
Dr. Messersmith trained in internal medicine at Massachusetts General Hospital / Harvard Medical School and did his Medical Oncology / Drug Development Fellowship at Johns Hopkins, where he was on the faculty from 2004-2007 as Assistant Professor in the GI Oncology and Drug Development programs. He joined the University of Colorado Cancer Center in August 2007 as the Director of Gastrointestinal Medical Oncology. He was appointed co-Leader of Developmental Therapeutics in 2010, and in 2014 became Division Head of Medical Oncology, which has >50 faculty.
His focus is on clinical and translational cancer research in gastrointestinal cancers. The comprehensive GI cancer program at Colorado includes multi-disciplinary GI cancer clinics, tumor boards, and research endeavors. He has held NIH and DOD grants, and has served as the principal investigator on >60 national and local therapeutic trials. As an active investigator in the developmental therapeutics laboratory, he is working on novel targeted agents and immunotherapies as well as correlative studies for use on human tissue samples.
Dr. Messersmith is a member of multiple national committees, including the NCI Colon Cancer Task Force, National Comprehensive Cancer Network (NCCN) Committee on Colon/Rectal/Anal Cancers (which sets treatment guidelines used internationally), NCCN Investigator Steering Committee, Medical Oncology Committee of the American Board of Internal Medicine (ABIM), and others.